Q4 2025 EPS Estimates for Amicus Therapeutics, Inc. Raised by Zacks Research (NASDAQ:FOLD)

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Zacks Research boosted their Q4 2025 earnings per share (EPS) estimates for Amicus Therapeutics in a research note issued on Wednesday, October 2nd. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.09 per share for the quarter, up from their prior estimate of $0.07. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.08) per share. Zacks Research also issued estimates for Amicus Therapeutics’ Q2 2026 earnings at $0.07 EPS and Q3 2026 earnings at $0.14 EPS.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.15) earnings per share.

A number of other equities research analysts also recently weighed in on FOLD. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective for the company. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a research report on Friday, September 20th. Finally, JPMorgan Chase & Co. lowered their price objective on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock opened at $10.60 on Friday. The firm’s fifty day moving average price is $11.11 and its 200 day moving average price is $10.64. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of -21.63 and a beta of 0.69. Amicus Therapeutics has a 12-month low of $9.02 and a 12-month high of $14.57.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds have recently bought and sold shares of FOLD. Wellington Management Group LLP boosted its holdings in Amicus Therapeutics by 101.9% during the fourth quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock valued at $215,546,000 after acquiring an additional 7,666,335 shares during the period. Blackstone Inc. acquired a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $35,008,000. Janus Henderson Group PLC raised its position in shares of Amicus Therapeutics by 20.1% during the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after buying an additional 2,307,385 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Amicus Therapeutics by 583.4% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company’s stock valued at $25,640,000 after buying an additional 1,858,100 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Amicus Therapeutics by 1,758.9% during the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock valued at $18,790,000 after buying an additional 1,792,277 shares during the last quarter.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,398,532.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 22,500 shares of company stock worth $244,875 in the last ninety days. Corporate insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.